Former Medtronic CEO exits retirement early to helm Immucor

William A. Hawkins, former chairman and CEO of Medtronic, will replace outgoing Immucor CEO Joshua Levine, after he steps down from the role Oct. 17, according to a statement from the company’s board of directors.

Hawkins’ career includes more than 30 years in medical technology companies, as well as roles in Washington, D.C., that helped shape healthcare policies and matters involving the FDA. Upon becoming CEO, Hawkins will also serve as senior advisor to TPG Capital, Immucor’s parent company.

Outgoing CEO Levine cited distance from his family as the reason for stepping down from the role.

The Norcross, Ga.-based company develops and sells reagents and systems used to detect and identify cell and serum components of human blood prior to blood transfusions.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.